109451
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
肝转移性喉部小涎腺癌：基于抗 EGFR 的联合疗法成功治疗一例报告及文献综述
Authors Guo Z , Li Q, Hong D, Wei Y, Wang Z
Received 7 June 2025
Accepted for publication 2 October 2025
Published 27 October 2025 Volume 2025:18 Pages 1195—1200
DOI https://doi.org/10.2147/OTT.S545401
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr John Maher
Zhigui Guo,1,* Qianwen Li,2,* Dan Hong,1 Yaning Wei,1 Zhiyu Wang1
1Hebei Key Laboratory of Cancer Radiotherapy and Chemotherapy, Department of Medical Oncology, Affiliated Hospital of Hebei University, Baoding, 071000, People’s Republic of China; 2Department of Gynecology, Affiliated Hospital of Hebei University, Baoding, 071000, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Zhiyu Wang, Hebei Key Laboratory of Cancer Radiotherapy and Chemotherapy, Department of Medical Oncology, Affiliated Hospital of Hebei University, No. 648 Dongfeng East Road, Baoding, 071000, People’s Republic of China, Email 18931200826@189.cn
Abstract: Laryngeal minor salivary gland carcinoma is a rare malignancy, accounting for less than 1% of laryngeal cancers. We present a case of a 43-year-old male with a history of surgically resected laryngeal ductal carcinoma who developed liver metastases. Initial pathology from the liver lesion was inconclusive, leading to a misdiagnosis of intrahepatic cholangiocarcinoma. After progression on first-line chemotherapy and immunotherapy, the diagnosis was revised to metastatic laryngeal minor salivary gland carcinoma, supported by positive EGFR expression. Second-line treatment with the anti-EGFR agent cetuximab, combined with immunotherapy and chemotherapy (sindilizumab, albumin-bound paclitaxel, and S-1), resulted in a sustained partial response. This case highlights the diagnostic challenges of this rare tumor and suggests the potential efficacy of anti-EGFR therapy in EGFR-expressing metastatic laryngeal salivary gland carcinoma. Given the rarity and aggressive nature of primary laryngeal salivary duct carcinoma, it remains a significant challenge for both diagnosis and treatment. The current case underscores the difficulty in identifying the primary tumor site, especially when metastasis occurs. Additionally, the effectiveness of anti-EGFR therapy in EGFR-expressing tumors offers a promising treatment avenue. Further research is essential to establish standardized treatment protocols, identify predictive biomarkers, and optimize combination strategies for this uncommon malignancy.
Keywords: laryngeal minor salivary gland carcinoma, secondary liver malignancy, anti-EGFR therapy, immune checkpoint inhibitors, case report
1Hebei Key Laboratory of Cancer Radiotherapy and Chemotherapy, Department of Medical Oncology, Affiliated Hospital of Hebei University, Baoding, 071000, People’s Republic of China; 2Department of Gynecology, Affiliated Hospital of Hebei University, Baoding, 071000, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Zhiyu Wang, Hebei Key Laboratory of Cancer Radiotherapy and Chemotherapy, Department of Medical Oncology, Affiliated Hospital of Hebei University, No. 648 Dongfeng East Road, Baoding, 071000, People’s Republic of China, Email 18931200826@189.cn
Abstract: Laryngeal minor salivary gland carcinoma is a rare malignancy, accounting for less than 1% of laryngeal cancers. We present a case of a 43-year-old male with a history of surgically resected laryngeal ductal carcinoma who developed liver metastases. Initial pathology from the liver lesion was inconclusive, leading to a misdiagnosis of intrahepatic cholangiocarcinoma. After progression on first-line chemotherapy and immunotherapy, the diagnosis was revised to metastatic laryngeal minor salivary gland carcinoma, supported by positive EGFR expression. Second-line treatment with the anti-EGFR agent cetuximab, combined with immunotherapy and chemotherapy (sindilizumab, albumin-bound paclitaxel, and S-1), resulted in a sustained partial response. This case highlights the diagnostic challenges of this rare tumor and suggests the potential efficacy of anti-EGFR therapy in EGFR-expressing metastatic laryngeal salivary gland carcinoma. Given the rarity and aggressive nature of primary laryngeal salivary duct carcinoma, it remains a significant challenge for both diagnosis and treatment. The current case underscores the difficulty in identifying the primary tumor site, especially when metastasis occurs. Additionally, the effectiveness of anti-EGFR therapy in EGFR-expressing tumors offers a promising treatment avenue. Further research is essential to establish standardized treatment protocols, identify predictive biomarkers, and optimize combination strategies for this uncommon malignancy.
Keywords: laryngeal minor salivary gland carcinoma, secondary liver malignancy, anti-EGFR therapy, immune checkpoint inhibitors, case report